The U.S. Court of Appeals for the Federal Circuit (CAFC) today affirmed a Patent Trial and Appeal Board (PTAB) ruling that claims of DexCom, Inc.’s patent for implantable glucose sensors were unpatentable as obvious. The CAFC opinion was authored by Judge Nina Y. Wang of the United States District Court for the District of Colorado, sitting by designation.
Recent Posts
- Squires Emphasizes AI, Dubs Inherited Backlog ‘An Absolute Dumpster Fire’ and a ‘Betrayal’
- Federal Circuit Clarifies Precedent on Pre-AIA Prior Art ‘By Another’
- Squires Restores PTAB’s RPI Identification Requirement to Exacting Pre-SharkNinja Standard
- Tariffs, Tech Wars, and Patent Turmoil: Navigating IP Strategy in a Rapidly Changing World | IPWatchdog Unleashed
- Life Sciences Masters Panelists Lament Mounting Policy Uncertainty
